Twelve healthy volunteers received single 400-mg oral doses of norfloxacin. During the ensuing 48 h, from 8.3 to 53.3% (mean, 28%) of this dose was recovered in the feces. Peak drug concentrations in fecal specimens ranged from 207 to 2,716 ,ug/g. Norfloxacin (MK-0366), an orally administered quinolinecarboxylic acid derivative chemically related to nalidixic acid, has substantial activity in vitro against members of the family Enterobacteriaceae, Pseudomonas aeruginosa, Campylobacter fetus subsp. jejuni, Vibrios spp., and Yersinia enterocolitica (2-6) and somewhat less activity against grampositive organisms such as streptococci, Staphylococci aureus, the enterococci, and Clostridium difficile (2-6). If adequate concentrations of the drug can be maintained in the large bowel, this spectrum of activity suggests that norfloxacin might be clinically useful in gut decontamination in neutropenic patients, prophylaxis in burn patients, prophylaxis and treatment of traveler's diarrhea, and surgical prophylaxis before elective colonic surgery. In this study concentrations of norfloxacin in fecal specimens were measured for 48 h after oral administration of a single dose.
Twelve healthy volunteers received single 400-mg oral doses of norfloxacin. During the ensuing 48 h, from 8.3 to 53.3% (mean, 28%) of this dose was recovered in the feces. Peak drug concentrations in fecal specimens ranged from 207 to 2,716 ,ug/g. Norfloxacin (MK-0366), an orally administered quinolinecarboxylic acid derivative chemically related to nalidixic acid, has substantial activity in vitro against members of the family Enterobacteriaceae, Pseudomonas aeruginosa, Campylobacter fetus subsp. jejuni, Vibrios spp., and Yersinia enterocolitica (2-6) and somewhat less activity against grampositive organisms such as streptococci, Staphylococci aureus, the enterococci, and Clostridium difficile (2) (3) (4) (5) (6) . If adequate concentrations of the drug can be maintained in the large bowel, this spectrum of activity suggests that norfloxacin might be clinically useful in gut decontamination in neutropenic patients, prophylaxis in burn patients, prophylaxis and treatment of traveler's diarrhea, and surgical prophylaxis before elective colonic surgery. In this study concentrations of norfloxacin in fecal specimens were measured for 48 h after oral administration of a single dose.
After The peak levels of norfloxacin were at least 290 ,ug/g of feces in each volunteer. Also, most volunteers had drug levels of greater than 50 p.g/g for at least 24 h. Since the norfloxacin MIC that inhibited 5Q% of members of the family F:nterobacteriaceae is less than 1 ,ug/ml and the 50% MIC for P. aeruginosa is 5 ,ug/nml (2-6), a single 400-mg oral dose of norfloxacin should produce sustained drug concentrations in feces many times higher than these MIC,s. Although in vivo activity of antibiotics in stool may not correlate, with in vitro activity, the drug levels obtained in this study appear to be high enough to warrant clinical evaluation.
